Falandry C, Rousseau F, Mouret-Reynier MA, et al. - Researchers sought to determine the optimal chemotherapy regimen for vulnerable older patients with ovarian cancer. In this randomized clinical trial, 120 vulnerable older patients with ovarian cancer were randomized to receive 6 cycles of (1) carboplatin, area under the curve (AUC) 5 mg/mL·min, plus paclitaxel, 175 mg/m², every 3 weeks; (2) single-agent carboplatin, AUC 5 mg/mL·min or AUC 6 mg/mL·min, every 3 weeks; or (3) weekly carboplatin, AUC 2 mg/mL·min, plus paclitaxel, 60 mg/m2, on days 1, 8, and 15 every 4 weeks. Outcomes suggest that single-agent carboplatin was less feasible and active when compared with a conventional every-3-weeks carboplatin–paclitaxel regimen (6 cycles completed in 48% vs 60% of patients, respectively), with significantly worse progression-free and overall survival outcomes, resulting in premature termination of the trial. Researchers recommend offering a conventional doublet regimen to all older adult patients with ovarian cancer despite relatively high toxic effects, irrespective of vulnerability.